Vimta Labs Ltd

- The company has not indicated any current or planned new fundraising through debt or equity. - The balance sheet remains net debt-free with cash and cash equivalents of INR398 million as of FY '23. - During the year, Vimta Labs repaid INR44 million of debt, reducing outstanding borrowings to INR150 million, with a very low debt-to-equity ratio of 0.05x. - Capital expenditure plans (around INR60 crores for capacity doubling at Genome Valley) are being funded from internal accruals and routine capex aligned with depreciation. - No mention of raising funds externally for growth or capex was made; focus is on managing cash flow and working capital efficiently. - Overall, the company is confident about funding its expansion through generated cash flows without resorting to external financing in the near future.

- Vimta Labs is undertaking a major capex of INR 60 crores to double capacities at the Genome Valley facility in Hyderabad, expected to complete by March FY '24. (Page 11, 16) - This INR 60 crores capex is specifically for infrastructure/building expansion; equipment will be purchased as needed separately. (Page 7, 11) - Approximately 20% of the INR 60 crores capex was spent in FY '23, with the remainder planned for FY '24. (Page 7) - Additional ongoing annual capex aligns with depreciation expenses to buy new technologies, replace equipment, and expand capacities incrementally. (Page 7) - Vimta Labs is also investing in new large molecule technologies (equipment presently being installed) to commercialize services from Q2 onward. (Page 17) - Capacity constraints persist, especially in pharma; new facilities opening by Q4 FY '24 are expected to relieve pressure. (Page 17) - The electronics and electrical testing division has had delayed scaling due to COVID, with plans to potentially add new chambers by 2025-26. (Page 13)

- Margins expected to improve going forward, driven primarily by volume growth across businesses (Page 17). - FY '24 growth target aims to improve upon last year's rate despite some capacity constraints, especially in pharma (Page 10). - Pharma segment capacity is severely constrained currently but expected to be managed until new facilities come online by Q4 FY '24 (Page 17). - Electronic and electrical testing division expected to scale up, potentially adding capacity (a chamber) by 2025-26, targeting INR30-40 crores revenue in a couple of years (Pages 9, 13). - Food division expected to cross INR100 crores revenue soon, with margins improving as volumes scale (Pages 10, 14). - Capacity expansion in Genome Valley (INR60 crores capex) completion by end FY '24 will support scaling towards INR500 crores midterm revenue target by 2026 (Pages 8, 11). - Growth in pharma services, especially biologics/large molecules, expected with new technologies being commercialized from Q2 FY '24 (Page 17). - Diagnostics growth to remain focused on B2B segment, with limited traction in B2C (Pages 8, 10, 16).

- Vimta Labs expects better margins going forward driven primarily by volume growth across business segments. - FY '24 growth target aims to improve over FY '23 despite capacity constraints, with strong growth particularly in pharma and food testing. - Preclinical & clinical research and large molecule services (biologics) are emerging as promising growth drivers. - Electronics and electrical testing segment is expected to scale up steadily with capacity expansions planned by 2025-26. - Capacity expansion in Genome Valley (INR 60 crores capex) to complete by end FY '24, enabling growth towards INR 500 crores revenue target by 2026. - Operating leverage and volume ramp-up should positively impact margins and earnings, although some divisions underperformed last year. - Strategically focusing on B2B diagnostics, which is more manageable and scalable. - Overall, confident on midterm targets with growth in revenues, operating profits, and margins improving steadily.

- The transcript does not explicitly provide specific figures or details regarding the current or expected order book or pending orders for Vimta Labs Limited as of May 2023. - However, it mentions that certain divisions did not grow as anticipated, which affected margins, indicating variability in order fulfillment or demand. - Capacity constraints exist, particularly in the pharma side, suggesting strong demand but limited ability to fully service orders at present. - New capacity expansions are underway and expected to be operational by Q4 FY '24, which should help manage order backlog and support growth. - Pharma large molecule services and diagnostics are areas of growing focus, likely implying incoming or expected orders post-installation of new technologies. - The company is confident of growth prospects and capacity expansion to reach INR 500 crores revenue target by 2026, indicating a positive outlook on incoming order flow.